In Brief
Refine Search
Biotechnology
Contract development and manufacturing organization (CDMO) Samsung Biologics has commenced operations at Plant 4, part of the world’s largest bio-manufacturing plant. 13 October 2022
Biotechnology
British T cell specialist Emergex Vaccines has acquired the assets of California’s Zosano Pharma, for an undisclosed amount. 12 October 2022
Biotechnology
Just days after confirming talks were in progress, UK and USA-based clinical-stage biotech PureTech today announced that it has mutually agreed with Nektar to terminate discussions regarding a possible business combination. 11 October 2022
Biotechnology
DNA sequencing firm Illumina has announced a strategic research collaboration with UK pharma major AstraZeneca. 11 October 2022
Biotechnology
Belgian startup Ziphius Vaccines is to collaborate with University Hospital Ghent (UZ Ghent) in a public-private partnership for the scale up and manufacturing of certain self-amplifying RNA vaccines. 7 October 2022
Biotechnology
Medicines regulator Health Canada has authorized Comirnaty Original & Omicron BA.4/BA.5 as a 30μg booster dose for individuals ages 12 years and older. 7 October 2022
Biotechnology
UK and USA-based clinical-stage biotech PureTech Health’s shares fell 17% to 213.50 pence in London on Friday morning, after the company confirmed that it has “exchanged indicative, non-binding proposals” with Nektar Therapeutics regarding a possible combination, which may include, amongst other things, an offer for share capital of PureTech. 7 October 2022
Biotechnology
Oxford BioTherapeutics has out-licensed to Genmab a novel antibody which forms part of its program of research in immuno-oncology. 4 October 2022
Biotechnology
US gene therapy company Voyager Therapeutics said today that Pfizer has exercised its option to license a next-generation capsid generated by Voyager’s TRACER capsid discovery platform in accordance with the agreement announced in October last year. 4 October 2022
Biotechnology
The US District Court for the Northern District of California has issued an order sustaining a jury verdict in favor of Plexxikon (the US subsidiary of Japan’s Daiichi Sankyo) on its claim that the US unit of Swiss pharma giant Novartis’ BRAF inhibitor Tafinlar (dabrafenib) infringes Plexxikon's US Patents 9,469,640 and 9,844.539. 3 October 2022
Biotechnology
Denmark-based SNIPR Biome has announced that its patent portfolio covering the use of CRISPR/Cas systems to edit prokaryotes is now available for academic and non-profit research use without a written license. 3 October 2022
Biotechnology
Pfizer and BioNTech have completed a submission to the European Medicines Agency to broaden the label for Comirnaty, to include a booster dose for children aged five to eleven. 29 September 2022
Biotechnology
In the USA, Vertex Pharmaceuticals and CRISPR Therapeutics have been granted a rolling review for their sickle cell disease (SCD) candidate exagamglogene autotemcel (exa-cel). 28 September 2022
Biotechnology
Marketed by AstraZeneca and Merck & Co, cancer drug Lynparza (olaparib) has now been approved in China for an additional indication. 22 September 2022
Biotechnology
Roivant has filed a form S-3 with the US Securities and Exchange Commission (SEC), registering several prospectuses offering shares worth a total of $1 billion. 20 September 2022
Biotechnology
French specialty vaccine company Valneva and Germany-based IDT Biologika have agreed to terminate their collaboration following the delivery of inactivated COVID-19 bulk vaccine to Valneva, and considering the current order levels and existing inventories. 19 September 2022
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) today recommended converting the conditional marketing authorizations of the COVID-19 vaccines Comirnaty (from BioNTech and Pfizer’s vaccine) and Spikevax (Moderna’s vaccine) into standard marketing authorizations. 16 September 2022
Biotechnology
BRIEF—Positive Phase III results reinforce potential benefit of Opdivo in earlier stages of melanoma
The Phase III CheckMate -76K trial evaluating Opdivo (nivolumab) in the adjuvant setting in completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis. 15 September 2022
Biotechnology
Carver Biosciences, a Boston, USA-based biotech focused on the development of CRISPR/Cas13 antivirals, today announced the closure of a $3 million seed round of financing led by Khosla Ventures. 15 September 2022
Biotechnology
Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, has announced the pricing of its upsized initial public offering of 10,900,000 shares of its common stock at a public offering price of $17 per share. 15 September 2022
Biotechnology
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Biotechnology
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Biotechnology
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Biotechnology
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Biotechnology
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
Biotechnology
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
Biotechnology
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Biotechnology
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Biotechnology
US clinical-stage biotech Spyre Therapeutics says it has appointed of Sheldon Sloan as its chief medical officer (CMO). 3 October 2024
Biotechnology
US biotech Triveni Bio has announced a $115 million Series B to support pipeline expansion. 3 October 2024
Biotechnology
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
Biotechnology
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Biotechnology
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Biotechnology
American biotech Shattuck Labs has announced plans to reduce its workforce by approximately 40%, bringing its employee count below 50. 2 October 2024
Biotechnology
Swiss drugmaker Ferring Pharmaceuticals has announced positive results from the OPTIMISE study in ulcerative colitis (UC). 2 October 2024
Biotechnology
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
Biotechnology
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze